The FDA recently approved Aimovig (erenumab-aooe), a new drug designed for the prevention of migraine. One writer for Inverse shared her personal experience with the medication, along with a rundown of what we know about the treatment and its efficacy. Science News also offered a look at the innovative drug and its mechanism of action.
The current price of Aimovig is high, nearly $7,000 a year. Manufacturers are offering coupons for two free injections (the injections are intended to be taken once monthly) to selected longtime migraine patients. More information about patient discounts and offers can be found here.
There's a lot of excitement in the patient and advocate community, mixed with some concern that the drug may have been fast-tracked to market before all side effects were thoroughly studied. For many people living with chronic migraine, though, this feels like a breakthrough.